www.fdanews.com/articles/87736-oncolytics-biotech-completes-enrollment-in-combination-reolysin-radiation-trial
ONCOLYTICS BIOTECH COMPLETES ENROLLMENT IN COMBINATION REOLYSIN/RADIATION TRIAL
June 20, 2006
Oncolytics Biotech has completed patient enrollment in its Phase Ia clinical trial investigating the use of Reolysin in combination with radiation to treat patients with advanced cancers.
A total of 11 patients were treated in the Phase Ia trial with two intratumoural treatments of Reolysin at several dosages with a constant localized radiation dose of 20 Gy in five fractions. A maximum tolerated dose was not reached and the combination treatment appears to have been well-tolerated by the patients.